All Posts
WHO adds Janssen vaccine to list of safe and effective emergency tools against COVID-19
14 Mar, 2021 | 20:57h | UTC
Commentary on Twitter (thread – click for more)
https://twitter.com/hildabast/status/1370537307392987141
[Preprint] RCT: Full-dose/therapeutic anticoagulation provides no benefit in critically ill patients with Covid-19
14 Mar, 2021 | 20:59h | UTCTherapeutic Anticoagulation in Critically Ill Patients with Covid-19-Preliminary Report – medRxiv
Related (results on moderately ill patients): [Not published yet] Full-dose Heparin best for moderate COVID-19 regardless of D-dimer — Data released from ACTIV-4a, ATTACC, and REMAP-CAP trials
Perspective | School reopening without robust COVID-19 mitigation risks accelerating the pandemic
14 Mar, 2021 | 20:51h | UTCSchool reopening without robust COVID-19 mitigation risks accelerating the pandemic – The Lancet
Covid vaccinations: No reason to stop using AstraZeneca jab, says WHO
14 Mar, 2021 | 20:46h | UTCCovid vaccinations: No reason to stop using AstraZeneca jab, says WHO
See also: Benefits Of AstraZeneca Vaccine Outweigh Risks, Say EMA and WHO Officials – Urging Jabs To Continue While Safety Data Around Blood Clots Is Reviewed – Health Policy Watch AND COVID-19 Vaccine AstraZeneca: PRAC investigating cases of thromboembolic events – vaccine’s benefits currently still outweigh risks – Update – European Medicines Agency AND Canada says AstraZeneca vaccine is safe after Norway and Denmark suspend use – Reuters
Urgent lessons from COVID 19: why the world needs a standing, coordinated system and sustainable financing for global research and development
14 Mar, 2021 | 20:47h | UTC
Commentary on Twitter
#COVID19 vaccines—developed, trialled, manufactured & authorised in several countries within a year. @VictorDzau et al. on lessons from the pandemic to inform an end-to-end global research & development preparedness & response ecosystem. Read https://t.co/G9PA5JBuaJ pic.twitter.com/EtFORBxvTl
— The Lancet (@TheLancet) March 12, 2021
Cohort study: Effectiveness of three vs. six feet of physical distancing for controlling spread of COVID-19 among primary and secondary students and staff
14 Mar, 2021 | 20:48h | UTC
Epidemiological and evolutionary considerations of SARS-CoV-2 vaccine dosing regimes
14 Mar, 2021 | 20:43h | UTCEpidemiological and evolutionary considerations of SARS-CoV-2 vaccine dosing regimes – Science
Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity
14 Mar, 2021 | 20:44h | UTCMultiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity – Cell
Commentary: Vaccine-induced antibodies may be less effective against several new SARS-CoV-2 variants
Commentary on Twitter (thread – click for more)
Our paper describing the potential for mRNA vaccines to induce antibodies capable of neutralizing many of the circulating variants is now available online at Cell!https://t.co/c8B87Tg55S pic.twitter.com/eRM8ABJrQY
— Balazs Lab (@BalazsLab) March 12, 2021
Cohort study: Association of ablative radiation therapy with survival among patients with inoperable pancreatic cancer
14 Mar, 2021 | 20:09h | UTCAssociation of Ablative Radiation Therapy With Survival Among Patients With Inoperable Pancreatic Cancer – JAMA Oncology (free for a limited period)
Commentary on Twitter
Ablative RT to 98Gy biologically effective dose following multiagent induction therapy for locally advanced pancreatic cancer (LAPC) was safe & resulted in durable locoregional tumor control & favorable survival https://t.co/pLf52Tt6j0 #GICSM
— JAMA Oncology (@JAMAOnc) March 12, 2021
Guide to enhanced recovery for cancer patients undergoing breast surgery and reconstruction
14 Mar, 2021 | 20:01h | UTC
Study: Healthcare settings did not increase the risk for Covid-19 infection among health care workers in the US. Exposure outside the workplace was the strongest risk factor for SARSCoV2 seropositivity
14 Mar, 2021 | 20:41h | UTCCommentaries: Healthcare settings do not increase risk for Covid-19 infection spread – University of Maryland School of Medicine AND Did Healthcare Workers Catch Covid In Or Outside The Hospital? – MedicalResearch.com AND Community Covid-19 Risk Higher Than Workplace Risk for Health Care Personnel – Physician’s Weekly
Commentary on Twitter
Cross-sectional study finds #COVID19 exposure outside the workplace was the strongest risk factor for #SARSCoV2 seropositivity. No workplace factors were associated with seropositivity. @EmoryMedicine @UMMC @HopkinsMedicine @CDCgov https://t.co/DbdSxTEb8n
— JAMA Network Open (@JAMANetworkOpen) March 10, 2021
70-gene signature as an aid for treatment decisions in early breast cancer: updated results of the phase 3 randomised MINDACT trial with an exploratory analysis by age
14 Mar, 2021 | 20:07h | UTC70-gene signature as an aid for treatment decisions in early breast cancer: updated results of the phase 3 randomised MINDACT trial with an exploratory analysis by age – The Lancet Oncology (link to abstract – $ for full-text)
Meta-analysis of observational studies suggests better long-term oncologic outcomes with propofol-based total intravenous anesthesia compared to any volatile anesthesia
14 Mar, 2021 | 19:59h | UTC
Commentary on Twitter
🔴 Patients who receive propofol-based TIVA for cancer surgery are associated with better overall survival than volatile anesthesia though there is no statistically significant difference in cancer-free survival between propofol-based TIVA https://t.co/lJHxmcqjtB pic.twitter.com/7gYmZYZRij
— Anesthesia&Analgesia (@IARS_Journals) March 3, 2021
Hearing loss prevalence and years lived with disability, 1990–2019: findings from the Global Burden of Disease Study 2019
12 Mar, 2021 | 08:16h | UTCCommentary: Addressing the global burden of hearing loss – The Lancet
Related: WHO Report: 1 in 4 people projected to have hearing problems by 2050
Commentary on Twitter
https://twitter.com/IHME_UW/status/1370167273407705089
Study shows increased risk of all-cause mortality in STEMI patients without standard modifiable risk factors
12 Mar, 2021 | 08:13h | UTC
Commentary on Twitter
#Swedish study published in @TheLancet shows patients with myocardial infarction without standard risk factors suffer worse outcomes. Use of guideline-indicated treatments attenuated the risk, underscoring a therapeutic need for this lower-risk group.https://t.co/U49IXNtACK
— The Lancet Reg Health-Europe (@LancetRH_Europe) March 10, 2021
Drug dosing in the critically ill obese patient: a focus on medications for hemodynamic support and prophylaxis
12 Mar, 2021 | 08:08h | UTC
M-A: Angiographic Patency of Coronary Artery Bypass Conduits
12 Mar, 2021 | 08:10h | UTC
Pragmatic RCT: No difference in outcomes from different gestational diabetes screening methods
11 Mar, 2021 | 08:12h | UTCA Pragmatic, Randomized Clinical Trial of Gestational Diabetes Screening – New England Journal of Medicine (link to abstract – $ for full-text)
Commentaries: One-Step Screening for Gestational Diabetes Increases Diagnoses — But Doesn’t Improve Outcomes – NEJM Journal Watch AND How Do Screening Methods for Gestational Diabetes Compare? – AJMC AND Different gestational diabetes screening methods cause no difference for complications – 2 Minute Medicine
Consensus Statement: Preoperative management of endocrine, hormonal, and urologic medications
11 Mar, 2021 | 08:04h | UTC
M-A: Early tracheostomy may lower the rates of ventilator-associated pneumonia and ventilator duration in critically ill patients
12 Mar, 2021 | 08:09h | UTCAuthor interview: Early vs Late Tracheotomy for Pneumonia and Ventilator Days
#Tracheostomy placement no more than 7 days after ventilator support may lower the rates of ventilator-associated pneumonia and ventilator duration https://t.co/gVPXoMEorN @Penn_ENT @UTHealthSA
— JAMA Otolaryngology – Head & Neck Surgery (@JAMAOto) March 11, 2021
AHA Scientific Statement | Opioid-Associated Out-of-Hospital Cardiac Arrest: Distinctive Clinical Features and Implications for Health Care and Public Responses
11 Mar, 2021 | 08:07h | UTC
[Press release – not published yet] Novavax reports 96% efficacy against original strain of COVID-19, 86% efficacy against B.1.1.7 variant, and 55% efficacy against B1.351 variant
12 Mar, 2021 | 08:33h | UTCPress release: Novavax Confirms High Levels of Efficacy Against Original and Variant COVID-19 Strains in United Kingdom and South Africa Trials
Commentaries: Novavax Reports Its COVID-19 Vaccine is 96% Efficacious, Based on Phase 3 Trial Results – TIME AND Novavax Says Vaccine Is 96% Effective At Preventing Original Covid-19 Virus – Forbes
Commentary on Twitter
https://twitter.com/m_scribe/status/1370126020121083913
ERS Guideline: Management of hospitalized adults with COVID-19
12 Mar, 2021 | 08:36h | UTC
NCCN Best Practices Guidance: Management of COVID-19 Infection in Patients with Cancer
12 Mar, 2021 | 08:31h | UTC
COVID-19 and liver disease: mechanistic and clinical perspectives
12 Mar, 2021 | 08:29h | UTC


